Guided Therapeutics Reports $462,742 Net Loss in Q1 2025, Focuses on LuViva Device Commercialization

Guided Therapeutics, Inc. reported a net loss of $462,742 for the first quarter of 2025, compared to a loss of $441,372 in the same period of 2024. The company did not generate any revenue from device sales during the quarter, maintaining a deferred revenue balance of $670,305, which is expected to be recognized once products are shipped. Operating expenses increased to $414,000 from $363,000 year-over-year, primarily due to higher research and development costs associated with clinical trials. The company’s accumulated deficit now stands at approximately $154.2 million.

In terms of financial position, Guided Therapeutics had total assets of $967,000 and total liabilities of $5.995 million as of March 31, 2025. The company’s cash reserves decreased to $115,000 from $388,000 at the end of 2024. Current liabilities included $5.899 million, with significant components being accounts payable and accrued liabilities. The company’s stockholders' deficit totaled approximately $5 million, reflecting ongoing operational losses.

Strategically, Guided Therapeutics is focused on the commercialization of its LuViva device, a non-invasive cervical cancer detection technology. The company is actively pursuing FDA approval through a clinical trial involving 400 participants, with 360 patients enrolled as of May 1, 2025. Additionally, the company is working towards regulatory approval in China, where its partner SMI has filed an application with the NMPA. The company anticipates generating approximately $2 million in sales over the next twelve months, contingent on securing additional purchase orders.

Operationally, Guided Therapeutics has made significant changes to its capital structure, including a private placement offering that raised $205,000. The company also engaged in debt exchanges with board members, converting $50,000 of notes payable into common stock and warrants, resulting in a loss on extinguishment of debt. The company’s employee headcount and operational capacity are expected to increase as it ramps up production to meet anticipated demand.

Looking ahead, Guided Therapeutics faces challenges in raising sufficient capital to fund its operations and FDA approval process. The company has indicated that it may need to curtail operations if it cannot secure additional funding. The management remains optimistic about the potential for product sales and market acceptance, but acknowledges the inherent risks and uncertainties in the medical device industry.